BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Talazoparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Talazoparib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04901702-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT04901702)
DESCRIPTION:Talazoparib\, phase 1/2.\nStudy: Study of Onivyde With Talazopa
 rib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarc
 oma\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04901702
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02286687-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT02286687)
DESCRIPTION:Talazoparib\, phase 2.\nStudy: Talazoparib in Treating Patients
  With Recurrent\, Refractory\, Advanced\, or Metastatic Cancers and Altera
 tions in the BRCA Genes\nEstimated primary completion: 31 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT02286687
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05873192-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT05873192)
DESCRIPTION:Talazoparib\, phase 2\, Prostate Cancer.\nStudy: Presurgical Ph
 ase II Study of Talazoparib in Combination With Enzalutamide in Prostate C
 ancer\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05873192
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05327010-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT05327010)
DESCRIPTION:Talazoparib\, phase 2.\nStudy: Testing the Combination of the A
 nti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Adv
 anced Solid Tumors\, The ComBET Trial\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talazopa
 rib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05327010
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Talazoparib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Talazoparib\, phase 3.\nStudy: Continued Access Study for Parti
 cipants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That 
 Are Closing\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05059522
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04039230-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT04039230)
DESCRIPTION:Talazoparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study to Evaluate Sacituzumab Govitecan in Combination With Talazop
 arib in Patients With Metastatic Breast Cancer.\nEstimated primary complet
 ion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ta
 lazoparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04039230
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03990896-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Talazoparib: Phase 2 readout est. (NCT03990896)
DESCRIPTION:Talazoparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Evaluation of Talazoparib\, a PARP Inhibitor\, in Patients With Somat
 ic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial\n
 Estimated primary completion: 31 March 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03990896
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101551-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Talazoparib: Phase 1 readout est. (NCT05101551)
DESCRIPTION:Talazoparib\, phase 1.\nStudy: Study of Talazoparib in Combinat
 ion With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Ef
 ficacy\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05101551
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03964532-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT03964532)
DESCRIPTION:Talazoparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: TALAVE: Induction Talazoparib Followed by Combination of Talazopari
 b and Avelumab in Advanced Breast Cancer\nEstimated primary completion: Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talazoparib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 64532
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892693-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Talazoparib: Phase 2 readout est. (NCT04892693)
DESCRIPTION:Talazoparib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Talazoparib in Advanced Breast Cancer Patients With Homologous Recomb
 inant Deficiency\nEstimated primary completion: 31 May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04892693
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04734730-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270823
DTEND;VALUE=DATE:20270824
SUMMARY:Talazoparib: Phase 2 readout est. (NCT04734730)
DESCRIPTION:Talazoparib\, phase 2\, Prostate Cancer.\nStudy: Talazoparib Wi
 th Androgen Deprivation Therapy and Abiraterone for the Treatment of Castr
 ation Sensitive Prostate Cancer\nEstimated primary completion: 23 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/talazoparib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04734730
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04170946-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Talazoparib: Phase 1 readout est. (NCT04170946)
DESCRIPTION:Talazoparib\, phase 1.\nStudy: Talazoparib and Thoracic RT for 
 ES-SCLC\nEstimated primary completion: September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04170946
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Talazoparib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Talazoparib\, phase 2.\nStudy: The Drug Rediscovery Protocol (D
 RUP Trial)\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03968406-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Talazoparib: Phase 1 readout est. (NCT03968406)
DESCRIPTION:Talazoparib\, phase 1.\nStudy: Talazoparib and Radiation Therap
 y in Treating Patients With Locally Recurrent Gynecologic Cancers\nEstimat
 ed primary completion: 1 October 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/talazoparib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03968406
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03672773-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Talazoparib: Phase 2 readout est. (NCT03672773)
DESCRIPTION:Talazoparib\, phase 2.\nStudy: Talazoparib and Low-Dose Temozol
 omide in Treating Participants With Relapsed or Refractory Extensive-Stage
  Small Cell Lung Cancer\nEstimated primary completion: 1 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03672773
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035745-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT05035745)
DESCRIPTION:Talazoparib\, phase 1/2\, Breast Cancer.\nStudy: Selinexor & Ta
 lazoparib in Advanced Refractory Solid Tumors\; Advanced/Metastatic Triple
  Negative Breast Cancer (START)\nEstimated primary completion: November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/talazoparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05035745
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04693468-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talazoparib: Phase 1 readout est. (NCT04693468)
DESCRIPTION:Talazoparib\, phase 1.\nStudy: Talazoparib and Palbociclib\, Ax
 itinib\, or Crizotinib for the Treatment of Advanced or Metastatic Solid T
 umors\, TalaCom Trial\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04693468
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Talazoparib\, phase 2.\nStudy: TAPUR: Testing the Use of Food a
 nd Drug Administration (FDA) Approved Drugs That Target a Specific Abnorma
 lity in a Tumor Gene in People With Advanced Stage Cancer\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/talazoparib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582628-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT06582628)
DESCRIPTION:Talazoparib\, phase 2\, Prostate Cancer.\nStudy: Talazoparib Pl
 us Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Can
 cer\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06582628
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319249-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Talazoparib: Phase 1/2 readout est. (NCT05319249)
DESCRIPTION:Talazoparib\, phase 1/2.\nStudy: Natural Killer Cell Immunother
 apy in Combination With PARP-inhibition in Acute Myeloid Leukemia\nEstimat
 ed primary completion: June 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/talazoparib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05319249
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511039-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Talazoparib: Phase 1 readout est. (NCT04511039)
DESCRIPTION:Talazoparib\, phase 1.\nStudy: Trifluridine/Tipiracil and Talaz
 oparib for the Treatment of Patients With Locally Advanced or Metastatic C
 olorectal or Gastroesophageal Cancer\nEstimated primary completion: 1 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talazopar
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4511039
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844383-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Talazoparib: Phase 2 readout est. (NCT06844383)
DESCRIPTION:Talazoparib\, phase 2\, Metastatic Castration-Resistant Prostat
 e Cancer.\nStudy: A Study of Talazoparib With or Without Enzalutamide in P
 eople With Prostate Cancer Who Have Previously Received Abiraterone Acetat
 e or Darolutamide\nEstimated primary completion: March 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/talazoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06844383
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05053854-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Talazoparib: Phase 1 readout est. (NCT05053854)
DESCRIPTION:Talazoparib\, phase 1.\nStudy: PARP Inhibitor With 177Lu-DOTA-O
 ctreotate PRRT in Patients With Neuroendocrine Tumours\nEstimated primary 
 completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/talazoparib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05053854
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06218628-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20290822
DTEND;VALUE=DATE:20290823
SUMMARY:Talazoparib: Phase 1 readout est. (NCT06218628)
DESCRIPTION:Talazoparib\, phase 1.\nStudy: Pacritinib w/ Talazoparib in Pts
  w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition\nEstimate
 d primary completion: 22 August 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/talazoparib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06218628
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Talazoparib\, phase 2\, Breast Cancer.\nStudy: I-SPY TRIAL: Neo
 adjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer\nEs
 timated primary completion: December 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05071937-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Talazoparib: Phase 2 readout est. (NCT05071937)
DESCRIPTION:Talazoparib\, phase 2.\nStudy: ZEN003694 Combined With Talazopa
 rib in Patients With Recurrent Ovarian Cancer\nEstimated primary completio
 n: 30 November 2033. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 talazoparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05071937
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-2243@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Talazoparib: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Talazoparib\, phase 2.\nStudy: Study to Investigate Outcome of 
 Individualized Treatment in Patients With Metastatic Colorectal Cancer\nEs
 timated primary completion: 31 December 2038. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/talazoparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/talazoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
